Abstracts Archive - Page 1868 of 2616 - ACR Meeting Abstracts

Abstract Number: 3073 • 2015 ACR/ARHP Annual Meeting
Patterns of Vascular Involvement in Childhood Takayasu Arteritis
Florence A. Aeschlimann¹, Simon Eng², Lars Grosse-Wortmann³, Susanne Benseler⁴, Ronald Laxer¹, Diane Hebert⁵ and Rae S.M. Yeung¹, ¹Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ²151 Beecroft Rd., Apt. 604, University of Toronto, Toronto, ON, Canada, ³Divisyon of Cardiologz, The Hospital for Sick Children, Toronto, ON, Canada, ⁴Pediatrics/Alberta Children's Hospital, Department of Pediatrics/University of Calgary, Calgary, AB, Canada, ⁵Division of Nephrology, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Takayasu arteritis (TA) is the most common large vessel vasculitis and may presents in childhood. Different angiographic classification systems based on adults with TA…
Abstract Number: 3074 • 2015 ACR/ARHP Annual Meeting
The Shared Rheumatoid Arthritis HLA-DRB1 Susceptibility Epitope Shapes the Molecular Orientation of Citrulline and the Autoreactive T Cell Receptor Repertoire
Jurgen van Heemst¹, Stephen Scally², Soi Cheng Law³, Diane van der Woude⁴, Carol Hitchon⁵, David B. Robinson⁶, T. W. J. Huizinga⁷, Hugh H Reid⁸, René E. M. Toes⁷, Hani El-Gabalawy⁹, Jamie Rossjohn¹⁰ and Ranjeny Thomas¹¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Monash University, Melbourne, Australia, ³The University of Queensland Diamantina Institute, Translational Research Institute, Princess Alexandra Hospital, Brisbane, Australia, ⁴Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁵University of Manitoba, Winnipeg, MB, Canada, ⁶Arthritis Center, University of Manitoba, Winnipeg, MB, Canada, ⁷Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁸Department of Biochemistry and Molecular Biology, School of Biomedical Sciences, Monash University, Clayton, Melbourne, Australia, ⁹University of Manitoba Arthritis Center, Winnipeg, MB, Canada, ¹⁰Institute of Infection and Immunity, Cardiff University, School of Medicine, Heath Park, Cardiff, England, ¹¹Translational Research Institute, The University of Queensland Diamantina Institute, Brisbane, Australia
Background/Purpose: Large-scale genomic studies have identified many genetic associations with autoimmune diseases, but the precise pathogenetic mechanisms by which the associated genes impact disease susceptibility…
Abstract Number: 3075 • 2015 ACR/ARHP Annual Meeting
Salivary Gland FcRL4+ B-Cells Are a Potential Source of Progenitor Cells for MALT Lymphoma in Primary Sjögren’s Syndrome
Erlin A. Haacke¹, Frans G.M. Kroese², Philip Kluin³, Petra M. Meiners⁴, Annie Visser⁵, Fred K.L. Spijkervet⁶ and Hendrika Bootsma⁷, ¹Pathology, University Medical Center Groningen, Groningen, Netherlands, ²Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ³Department of Pathology and Medical Biology, UMCG Groningen, Groningen, Netherlands, ⁴Oral and Maxillofacial Surgery, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ⁵Rheumatology and Clinical Immunology, UMC Groningen, Groningen, Netherlands, ⁶Oral and Maxillofacial Surgery, University Medical Center Groningen, Groningen, Netherlands, ⁷Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
Background/Purpose: Patients with primary Sjögren's Syndrome (pSS) have an increased risk of non-Hodgkin's lymphoma, predominantly of the Mucosa Associated Lymphoid Tissue (MALT) type, which commonly…
Abstract Number: 3076 • 2015 ACR/ARHP Annual Meeting
Interferon Gamma (IFNg) Is the Driving Mediator of Secondary Hemophagocytic Lymphohistiocytosis (sHLH) in TLR9-Mediated Pathogenesis in Mice and Is Correlated to Disease Parameters in Children
Cristina De Min¹, Vanessa Buatois¹, Laurence Chatel¹, Laura Cons², Francoise Richard³, Claudia Bracaglia⁴, Fabrizio De Benedetti⁵, Marie Kosco-Vilbois¹ and Walter Ferlin¹, ¹NovImmune S.A., Geneva, Switzerland, ²NovImmune S.A., Plan-Les-Ouates, Geneva, Switzerland, ³NovImmune SA, Geneva, Switzerland, ⁴Pediatric Medicine, Division of Rheumatology, Rome, Italy, ⁵Division of Rheumatology, Department of Pediatric Medicine, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy
Background/Purpose: Life-threatening hyperinflammatory syndromes caused by severe hypercytokinemia include primary (p) and secondary (s) hemophagocytic lymphohistiocytosis (HLH). Increased circulating levels of interferon gamma (IFNg) in…
Abstract Number: 3077 • 2015 ACR/ARHP Annual Meeting
Anakinra in Patients with Cortico-Dependent Idiopathic Recurrent Pericarditis: A Randomised Double-Blind Placebo-Controlled Withdrawal Trial
Antonio Brucato¹, Massimo Imazio², Silvia Maestroni¹, Davide Faustino Cumetti³, Anna Valenti¹, Renzo Marcolongo⁴, George Lazaros⁵, Mara Carraro², Fiorenzo Gaita², Gian Luca Erre⁶, Martina Finetti⁷, Marco Gattorno⁷ and Alberto Martini⁸, ¹Internal Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy, ²Cardiology, Maria Vittoria Hospital, Torino, Italy, ³Internal Medicine, Internal Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy, ⁴Clinical Immunology, Hospital of Padova, Padova, Italy, ⁵Department of Cardiology, Hippokration General Hospital, Athens, Greece, ⁶Rheumatology, Hospital of Sassari, Sassari, Italy, ⁷Pediatry, G. Gaslini Institute, Genova, Italy, ⁸Istituto G. Gaslini, Pediatria II, PRINTO, and University of Genoa, Genoa, Italy
Background/Purpose: Patients with recurrent pericarditis either do not respond or are intolerant to treatment with NSAIDs drugs, corticosteroids and colchicine. We aimed to assess the…
Abstract Number: 3078 • 2015 ACR/ARHP Annual Meeting
ABCG2 rs2231142 predicts Poor Response to Allopurinol in Patients with Gout
Lisa K. Stamp¹, Mary Wallace², Tony R. Merriman³, Amanda Phipps-Green⁴, Ruth Topless^4,5, Jill Drake⁶, Paul Tan⁷, Nicola Dalbeth⁸ and Rebecca Roberts⁴, ¹Medicine, University of Otago, Christchurch, Christchurch, New Zealand, ²Surgical Sciences, University of Otago, Dunedin, New Zealand, ³Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand, ⁴University of Otago, Dunedin, New Zealand, ⁵Department of Biochemistry, University of Otago, Dunedin, New Zealand, ⁶Rheumatology, Immunology and Allergy, Christchurch Hospital, Christchurch, New Zealand, ⁷University of Auckland, Auckland, New Zealand, ⁸Department of Medicine, University of Auckland, Auckland, New Zealand
Background/Purpose: Many patients fail to reach target serum urate (SU) on allopurinol. Although the most common causes of inadequate response are non-adherence and low dosing…
Abstract Number: 3079 • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety of Riociguat in Patients with Pulmonary Arterial Hypertension (PAH) Associated with Connective Tissue Disease (CTD)
Christopher P. Denton¹, J. Gerry Coghlan², Hossein-Ardeschir Ghofrani³, Friedrich Grimminger³, Jianguo He⁴, Gabriela Riemekasten⁵, Dario Vizza⁶, Annette Boeckenhoff⁷, Christian Meier⁸, Janethe de Oliveira Pena⁹ and Marc Humbert¹⁰, ¹Centre for Rheumatology and Connective Tissue Disease, UCL Medical School Royal Free Campus, London, United Kingdom, ²Royal Free London NHS Foundation Trust, London, England, ³University of Giessen and Marburg Lung Center, Giessen, Germany, ⁴Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ⁵Clinic of Rheumatology and Clinical Immunology, Berlin, Germany, ⁶La Sapienza University of Rome, Rome, Italy, ⁷Bayer Pharma AG, Wuppertal, Germany, ⁸Bayer Pharma AG, Berlin, Germany, ⁹Bayer HealthCare Pharma, Whippany, NJ, ¹⁰Université Paris-Sud, Laboratoire d’Excellence en Recherche sur le Médicament et Innovation Thérapeutique, and INSERM Unité 999, Le Kremlin–Bicêtre, France
Background/Purpose: PAH associated with CTD (PAH-CTD) has a worse prognosis than idiopathic/familial PAH. Here we report a prospective subgroup analysis of patients with PAH-CTD from…
Abstract Number: 3080 • 2015 ACR/ARHP Annual Meeting
Histone H2AX Phosphorylation As a Measure of DNA Double Strand Breaks and a Marker of Environmental Stress and Disease Activity in Lupus
Rajaie Namas, Paul Renauer, Mikhail Ognenovski, Pei-Suen Tsou and Amr H. Sawalha, Division of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Studies suggested that defective or inefficient DNA double strand break (DSB) repair results in failure to preserve genomic integrity leading to apoptotic cell death,…
Abstract Number: 3081 • 2015 ACR/ARHP Annual Meeting
IRF5 Deletion Prevents the SLE-like Disease Initiated By Dendritic Cell-Specific Loss of Caspase 8
Carla M. Cuda¹ and Harris R. Perlman², ¹Rheumatology, Northwestern University, Chicago, IL, ²Feinberg School of Medicine, Northwestern University, Chicago, IL
Background/Purpose: Previous studies implicate dendritic cells (DCs) in the initiation and persistence of systemic lupus erythematosus (SLE). While DCs from SLE patients exhibit elevated activation,…
Abstract Number: 3082 • 2015 ACR/ARHP Annual Meeting
Nanogel Based Delivery of an Inhibitor of Calcium/ Calmodulin- Dependent Protein Kinase 4 Suppresses Experimental Autoimmune Encephalomyelitis and Lupus-like Disease in Mice
Kotaro Otomo¹, Tomohiro Koga², Nobuya Yoshida³, Masayuki Mizui⁴, Christina Kriegel⁵, Tarek Fahmy⁶ and George C. Tsokos³, ¹Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ²Department of Rheumatology, Unit of Translational Medicine, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan, ³Division of Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ⁴Department of Nephrology, Osaka University Graduate School of Medicine, Osaka, Japan, ⁵Department of Biomedical Engineering, Yale University, New Heaven, CT, ⁶Biomedical and Chemical Engineering, Yale University, New Heaven, CT
Background/Purpose: Treatment of autoimmune diseases is still based on the use of general immunosuppressive drugs which invariably cause severe side effects. This fact has compelled…
Abstract Number: 3083 • 2015 ACR/ARHP Annual Meeting
Antibody Array Based Proteomic Screening of 274 Serum Markers in Systemic Lupus Erythematosus
Tianfu Wu¹, Huihua Ding², Cristina Arriens³, Chungwen Wei⁴, Jennifer H. Anolik⁵, David R. Karp³, Nancy J. Olsen⁶, Michelle Petri⁷, Ignacio Sanz⁴, Ramesh Saxena⁸ and Chandra Mohan², ¹Department of Biomedical Engineering, University of Houston, Houston, TX, ²Biomedical Engineering, University of Houston, Houston, TX, ³Internal Medicine - Rheumatic Diseases, University of Texas Southwestern Medical Center, Dallas, TX, ⁴Rheumatology, Emory University, Atlanta, GA, ⁵University of Rochester Medical Center, Rochester, NY, ⁶Divsion of Rheumatology, Department of Medicine, Penn State MS Hershey Medical Center, Hershey, PA, ⁷Rheumatology, Johns Hopkins University Hospital, Baltimore, MD, ⁸Nephrology, University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Given that early detection of renal involvement in systemic lupus erythematosus (SLE) and prompt management of the disease can have a significant impact on…
Abstract Number: 3084 • 2015 ACR/ARHP Annual Meeting
Progression of Lupus Pathology Is Correlative with Cardiac Magnetic Resonance Imaging Abnormalities, Diminished Function, and Inflammatory Histopathology in an Animal Model
Nicholas Young¹, Jeffrey Hampton¹, Saba Aqel¹, Jessica Pyles², Anna Bratasz², Anuradha Kalyanasundaram³, Wael N. Jarjour⁴ and Stacy P. Ardoin⁵, ¹Immunology and Rheumatology, The Ohio State University Medical Center, Columbus, OH, ²Small Animal Imaging Core, The Ohio State University Medical Center, Columbus, OH, ³Physiology and Cell Biology, The Ohio State University Medical Center, Columbus, OH, ⁴Department of Internal Medicine, Division of Immunology and Rheumatology, The Ohio State University Medical Center, Columbus, OH, ⁵Pediatric & Adult Rheumatology, Ohio State University, Columbus, OH
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease causing inflammation throughout the body and cardiovascular involvement is a significant contributor to morbidity and mortality…
Abstract Number: 3085 • 2015 ACR/ARHP Annual Meeting
Platelet Activation and Endothelial Reactivity in the Pathogenesis of Tissue Inflammation/Injury in Systemic Lupus Erythematosus
Robert Clancy¹, Sokha Nhek², Jonathan Newman³, Janet Nwaukoni¹, Sara Rasmussen⁴, Jill P. Buyon¹, Maya Rubin⁵, Kristen Lee¹ and Jeffrey Berger⁵, ¹Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ²New York University School of Medicine, New York, NY, ³Medicine, New York University School of Medicine, New York, NY, ⁴Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁵Medicine, Division of Cardiology, New York University School of Medicine, New York, NY
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are at increased risk for widespread endothelial dysfunction, vascular thromboses, and premature cardiovascular disease. Enhanced platelet activation and…
Abstract Number: 3086 • 2015 ACR/ARHP Annual Meeting
The Same Multidimensional Patient Health Assessment Questionnaire Used to Assess RAPID3 in Rheumatoid Arthritis, Osteoarthritis and Other Rheumatic Diseases Can Provide Quantitative Clues to Recognize and Document Comorbid Fibromyalgia
Kathryn A. Gibson¹, Annie Huang² and Theodore Pincus², ¹Liverpool Hospital, Liverpool, Australia, ²Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: An MDHAQ/RAPID3 (Multidimensional Health Assessment Questionnaire/Routine Assessment of Patient Index Data) is a 2 sided, 1 page questionnaire which is completed by patients in…
Abstract Number: 3087 • 2015 ACR/ARHP Annual Meeting
Cell Bound Complement Activation Products in Multianalyte Assay with Algorithm Have Utility in Distinguishing Primary Fibromyalgia from Systemic Lupus Erythematosus
Daniel Wallace¹, Stuart L. Silverman², Derren Barken³, John Conklin⁴ and Thierry Dervieux⁵, ¹Cedars-Sinai/UCLA, Los Angeles, CA, ²OMC Clinical Research Center, Beverly Hills, CA, ³Exagen Diagnostics, Vista, CA, ⁴1261 Liberty Way Suite C, Exagen Diagnostics, Vista, CA, ⁵Research and Development, Exagen Diagnostics, Vista, CA
Background/Purpose : Our objective was to prospectively establish the performance characteristics of a cell bound complement activation products (CB-CAPS) in a multi-analyte assay with algorithm…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].